Critiquing the Critics on Orac’s Respectful Insolence blog: Part III

Burzynski: Cancer is Serious Business, Part II
http://scienceblogs.com/insolence/2013/03/14/five-things-i-learned-second-hand-from-the-recent-screening-of-burzynski-cancer-is-serious-business-part-2

#37 – Denice Walter – March 14

“Milk kills”

Yes, it does:
https://www.google.com/search?q=%22Milk+kills%22&hl=en&client=safari&tbm=isch&tbo=u&source=univ&sa=X&ei=gXFIUZOHOvi04APZ24DoCQ&ved=0CDIQsAQ&biw=320&bih=416

#38 – Sirhcton – March 14

“. . .he’s never, despite having had over 60 phase II trials, published a complete phase II trial. . .

To abuse a meme: “I don’t have to show you any stinkin’ data!”

Just continue to do what you do best … ignore the information that is already out there:

2/24/2013
http://www.skeptical.gb.net/blog/?p=1442

2/27/2013
http://www.skeptical.gb.net/blog/?p=1798

3/9/2013
http://www.thetwentyfirstfloor.com/?p=8001

#41 – Krebiozen – March 14

“Denice,
to Mikey, ‘guns don’t kill people, processed milk kills people’”

You should really enjoy THIS, then:

#42 – Bob G Los Angeles – March 14

To Herr Doktor:

“The next time they do one of these B2 shows, where they screen the film and take questions, why doesn’t somebody just ask for the data right then and there — How many patients over the course of the years, including the fraction who are still alive, the fraction who died, and the fraction whose survival is unknown?

They will get used to hearing that question and do their best to adapt, but just making stuff up will have consequences of its own”

Why not just ask Dolcefino ?

#43 – Mark Thorson – March 14

“I have never heard of ANTINEOPLASTONS,” said Yu Xiong, deputy president of the Shanghai Institute of Pharmaceutical Industry”
http://usa.chinadaily.com.cn/china/2012-02/02/content_14528005.htm

Why should we care what Yu Xiong knows or does NOT know?
http://www.zoominfo.com/#!search/profile/person?personId=596114575&targetid=profile

With a population of 1,344,130,000 – 2011, I guess he does NOT keep up with:

10/29/2010 – ANTINEOPLASTONS:

New Perspectives on Innovative Drug Discovery: An Overview

CHINA:
Beijing University of Chinese Medicine

Hong Kong Baptist University

Chinese Academy of Medical Science & Peking Union Medical College

Hong Kong Polytechnic University

Hong Kong University of Science & Technology

9/1/2010 Received
9/22/2010 Revised
10/28/2010 Accepted
10/29/2010

(pg. 8 of 22 – actual pg. 457)
Human-derived compounds – ANTINEOPLASTONS and CDA-2

Urine and urine extracts have been used for therapeutic purposes for centuries, and the first identified active componentis 3 – phenylacetylamino – 2, 6 – piperidinedione (also called ANTINEOPLASTON A10)
http://ejournals.library.ualberta.ca/index.php/JPPS/article/download/9147/7453

10/1/2010 – ANTINEOPLASTON A10 – CHINA
http://www.springerlink.com/content/tj0177485773007t

(S)-2-((S)-2-(4-(3-[18F]fluoropropyl)benzamido)-3-phenylpropanamido)pentanedioic acid labeled with 18F
http://link.springer.com/article/10.1007%2Fs10967-010-0633-2?LI=true

Journal of Radioanalytical and Nuclear Chemistry
October 2010, Volume 286, Issue 1, pp 135-140
DOI 10.1007/s10967-010-0633-2

CHINA:
Key Laboratory of Radiopharmaceutical, College of Chemistry, Beijing Normal University, Beijing

PET Center of Xuan Wu Hospital, Beijing

Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing

#Burzynski References: 5. – 6.

As degradation product of ANTINEOPLASTON A10 in vivo, phenylacetyl glutamine (PG) showed antitumor activities

According to literatures, we designed and radiosynthesized a phenylacetyl glutamine (PG) derivative, which was achieved under a mild reaction condition

Evaluations in vitro and in vivo were performed on tumor bearing mice

Excitingly, the radiochemical purity was 98%, and besides the best radiochemical yield was up to 46%

it showed satisfied stability in vitro and in vivo

the results revealed it might become a potential PET imaging agent for detecting tumors

4/15/2009 – ANTINEOPLASTON AS2-5 – CHINA
3/14/2008 – Epub

http://www.ncbi.nlm.nih.gov/m/pubmed/19339187

Bioorg Med Chem. 2009 Apr 15;17(8):3061-71. doi: 10.1016/j.bmc.2009.03.017. Epub 2009 Mar 14
Bioorganic & Medicinal Chemistry
Volume 17, Issue 8, 15 April 2009, Pages 3061–3071

School of Pharmaceutical Sciences, Shandong University, No. 44 WenhuaXi Road, Ji’nan, Shandong Province, PR CHINA

Novel aminopeptidase N inhibitors derived from ANTINEOPLASTON AS2-5 (Part II)
http://www.sciencedirect.com/science/article/pii/S0968089609002478

4/15/2009 – ANTINEOPLASTON AS2-5 – CHINA
3/6/2009 – ePub

http://www.ncbi.nlm.nih.gov/m/pubmed/19329328
Bioorg Med Chem. 2009 Apr 15;17(8):3053-60. doi: 10.1016/j.bmc.2009.02.063. Epub 2009 Mar 6
Bioorganic & Medicinal Chemistry
Volume 17, Issue 8, 15 April 2009, Pages 3053–3060

School of Pharmaceutical Sciences, Shandong University, No. 44 WenhuaXi Road, Ji’nan, Shandong Province, PR CHINA

Novel aminopeptidase N inhibitors derived from ANTINEOPLASTON AS2-5 (Part I)
http://www.sciencedirect.com/science/article/pii/S0968089609002041

2007- ANTINEOPLASTON A10 – CHINA
http://ar.iiarjournals.org/content/27/4B/2427.short

Induction of apoptosis in human hepatocellular carcinoma cells by synthetic ANTINEOPLASTON A10

ANTICANCER RESEARCH 27: 2427-2432 (2007)

1/24/2007 Received
3/27/2007 Accepted

School of Pharmaceutical Sciences, Shandong University, Jinan

Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan, CHINA

Department of Applied Biochemistry, Tokai University, Kanagawa

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,
Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

http://ar.iiarjournals.org/content/27/4B/2427.full.pdf

Burzynski References: 1, 3, 5, 13 and 15
Egypt ANTINEOPLASTON A-10 References: 2 and 20

1990 – ANTINEOPLASTON A10 – CHINA
http://www.ncbi.nlm.nih.gov/m/pubmed/2092962

Studies of the release rate and bioavailability of ANTINEOPLASTON A10 capsule

Shandong Medical University, Department of Pharmacy, Jinan, CHINA

Drugs Exp Clin Res 16 (7): 357-9 (1990), PMID .2092962
Drugs Exp Clin Res. 1990;16(7):357-9

1990 – ANTINEOPLASTON A10 – CHINA
http://www.ncbi.nlm.nih.gov/m/pubmed/2092961

Pharmacokinetic study of radioactive ANTINEOPLASTON A10 in rats and mice

Shandong Medical University, Department of Pharmacy, Jinan, CHINA

Drugs Exp Clin Res 16 (7): 351-5 (1990), PMID .2092961
Drugs Exp Clin Research
Drugs Exp Clin Res. 1990;16(7):351-5

#45 – Narad – March 14

““I have never heard of antineoplastons,” said Yu Xiong, deputy president of the Shanghai Institute of Pharmaceutical Industry

“Finally, barking up the right squirrel””

Another EPIC Burzynski Critic FAIL

#46 – herr doktor bimler – March 15

“From Mark Thorson’s link:

Li Qingchen, a doctor and member of Scientific Squirrels, a Chinese organization dedicated to the dissemination of scientific knowledge, said Thursday that the American Academy of Anti-Aging Medicine (A4M) has been using an unapproved cancer therapy to swindle Chinese patients

[…]

The Chinese representative office of A4M claimed on its website that it could offer a “breakthrough cancer therapy” developed by Dr. Stanislaw Burzynski, who asserts that cancer can be treated with ANTINEOPLASTONS, a group of amino acids and petides normally found in urine and blood

The organization also posted dozens of promotional videos and blogs on Sina Weibo, a popular Chinese microblogging site

Sounds like the international trade in snake oil has run into CITES regulations

What’s the story with AAAAM?

On first glance it’s a umbrella organisation for a heterogeneous mixture of shysters and charlatans, including Burzynski’s “Aminocare” sideline”

You mean ANTINEOPLASTONS which have the same main ingredient as CDA-2 (CDA-H or CDA-II) ?

“Phase I/II/III clinical trials of CDA-2 have been completed in China in 2003

In August 2004, the State Drug Administration (SDA) of China approved the use of CDA-2 as an anticancer drug in solid tumors.”
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117

“CDA-2 had been approved as a first class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both side of Taiwan Strait.”
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21

8/17/2005 – New anti-cancer medicine invented in east China

8/15/2005 – Professor Ming C. Liau, laboratory in Everlife Pharmaceutical Co,. Ltd. in Hefei, capital of east China’s Anhui Province

Professor Liau began his research on cancer since 1962

In 1975, he found out that methylation enzymes play a central role in the regulation of cell replication and differentiation, and by controlling these enzymes, cancer could be healed
http://english.people.com.cn/200508/17/eng20050817_202981.html

1986-1992 he worked and published with Burzynski

1992

LIAU. M.C.• Liau. C.P.• Burzynski. S.R.
Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals
lnternat J Exptl Clin Chemother 1992;S:9-17

1992

LIAU, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug induced DNA hypermethylation by antineoplaston components
Internal J Exptl Clin Chemother 1992;S:19-27

1992

LIAU, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug-induced DNA hypermethylation by antineoplastons
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany

1990

Kampalath, B.N., LIAU, M.C., Burzynski, B., Burzynski, S.R.
Protective effect ofantineoplaston A10 in hepatocarcinogenesis induced by aflatoxin 81
Internal J Tissue Reactions 1990;12 (supp1):43-SO

1990

LIAU, M.C., Lee, S.S., Burzynski, S.R
Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5
Internat J Tissue Reactions 1990; 12 (suppl): 27-36

1990

LIAU, M.C.• Ashraf. A.a.. Lee. S.S.• Hendry, L.B., Burzynski. S.R.
Riboflavin as a minor active anticancer component of antineoplaston A2 and A5
Internal J Tissue Reactions 1990;12:19-26

1990

LIAU, M.C., Lee, S.S., Burzynski, S.R.
Separation of active anticancer components of antineoplaston A2, A3, and A5
Internat J Tissue Reactions 1990; 12 (suppl): 1-17

1989

LIAU, M.C., Lee, S.S., Burzynski, S.R
Hypomethylation of nucleic acids:
A key to the induction of terminal
differentiation
Internal J Exptl Clin Chemother 1989;2:187-199

1988

LIAU, M.C., Lee, S.S, Burzynski, S.R
Differentiation inducing components of antineoplaston A5
Adv Exptl Clin Chemother. 1988; 6: 9-2S

1987

Kampalath, B.N., LIAU, M.C., Burzynski, B., Burzynski, S.R.
Chemoprevention by antineoplastonA10 ofbenzo (a) pyrene-induced pulmonary neoplasia
Drugs Exptl Clin Res 1987;13 (suppl 1):S1-SS_

1987

LIAU, M.C., Szopa, M., Burzynski, B., Burzynski, S.R
Chemoswveillance:
A novel concept of the natural defense mechanism against cancer
Drugs Exptl Cline Res 1987;13 (suppl 1):71-76

1987

LIAU, M.C., Szopa, M., Burzynski, B., Burzynski, S.R_
Quantitative assay of plasma and urinary peptides as an aid for the evaluation ofcancer patients undergoing antineoplaston therapy.
Drugs Exptl Clin Res 1987;13 (suppl 1) :6 1-7 0

1987

Ashraf, A Q., LIAU, M.C., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic study of radioactive antineoplaston A10followingoraladministrationinrats_
DrugsExptlClinRes 1987;13(suppi1):4S-SO_

1986

Ashraf, AQ., LIAU, M.C., Mohabbat, M.O., Burzynski, S.R_
Preclinical studies ofantineoplastonA10 injections_
Drugs Exptl Clin Res 1986;12 (suppl 1):37-4S

1986

LIAU, M.C., Burzynski, S R
Altered methylation complex isoenzymes as selective targets for cancer chemotherapy
Drugs Exptl. Clin. Res. 12 (Suppl. 1):77-86
Drugs Exptl Clin Res 1986:12 (Suppl. 1):77-86

Advertisements

Burzynski, Ming-Cheng Liau, and Gi-Ming Lai

Ming C. Liau (Ming-Cheng Liau or M.C. Liau)
worked and published with Burzynski from 1986 – 1994 and worked on CDA-2 (CDA-II or CDA- H) in Taiwan, Republic of China
http://english.people.com.cn/200508/17/eng20050817_202981.html
Ming-Cheng Liau Patents
http://www.patentmaps.com/inventor/Ming-Cheng_Liau_1.html
Gi-Ming Lai, M.D. (GM Lai) also worked on CDA-2
http://faculty.nhri.org.tw/list_new2.php?indx=154
“Phase I/II/III clinical trials of CDA-2 have been completed in China in 2003
In August 2004, the State Drug Administration (SDA) of China approved the use of CDA-2 as an anticancer drug in solid tumors”
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117
“CDA-2 had been approved as a first class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both side of Taiwan Strait.” http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
CDA-2 (cell differentiation agent 2) is a urinary preparation that isolated from healthy human urine in China
J Pharm Pharmaceut Sci (www.cspsCanada.org) 13(3) 450 – 471, 2010
New Perspectives on Innovative Drug Discovery: An Overview
(pg. 8 of 22: Human-derived compounds – Antineoplastons and CDA-2) Starting at middle of left page:
http://ejournals.library.ualberta.ca/index.php/JPPS/article/download/9147/7453

Burzynski and Taiwan, ROC

M.C. Liau published with Burzynski from 1986 – 1992 and 1994

2001 – Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain
http://www.ncbi.nlm.nih.gov/m/pubmed/11321484
CDA-II, a preparation of HUMAN URINE
– …, LIAU MC, …
Department of Pharmacology, China Medical College, Taichung, Taiwan, ROC
Am J Chin Med. 2001;29(1):91-9
American Journal of Chinese Medicine, Vol. 29, No. 1, pp. 91–99
2001 Institute for Advanced Research in Asian Science and Medicine
Burzynski Reference: 3.
Samid Reference: 29. (who learned from Burzynski re Phenylacetate)
http://www.worldscientific.com/doi/abs/10.1142/S0192415X01000101
PDF
http://www.worldscientific.com/doi/pdf/10.1142/S0192415X01000101
PDF+
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X01000101
PDF+
References:
1988 – 3. BURZYNSKI, S.R. – … antineoplastons
1992 – 29. SAMID, D., S. … – Phenylacetate: …
Cited by:
1/2009 – China – 1. CDA-II, a URINARY …
2008 – China – 2. HUMAN URINE extract CDA-2 …
10/2005 – Taiwan, ROC – 3. … HUMAN URINE Extract
6/2005 – China – 4. Anti-tumor effect of CDA-II …
2003 – China / Taiwan, ROC – 5. …, Ming-Cheng LIAU, … Effect of CDA-II …
2002 – CHEN CH, … – CDA-Ⅱ … The 7th Taiwan Joint Cancer Conference ([ Conference Abstracts] Reference 5.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2002 – … HUMAN URINE extract CDA-Ⅱ … The 7th Taiwan Joint Cancer Conference ([Conference Abstracts] Reference 6. and 7.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – … , CHEN CH, … – CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] Reference 4.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – HUMAN URINE Extract CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] References 2. and 3.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – CHEN CH, – … CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] Reference 1.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid
1/2003 – Effect of CDA-II on cell viability, lipid peroxidation, glutathione concentration and its related enzyme activities in primary rat hepatocytes
http://www.ncbi.nlm.nih.gov/m/pubmed/12943172
Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration and Its Related Enzyme Activities in Primary Rat Hepatocyte
CDA-II (cell differentiation agent: a preparation of HUMAN URINE)
MC LIAU et al
Department of Pharmacology, China Medical College, Taichung, Taiwan, ROC
Am J Chin Med. 2003;31(3):415-23
The American Journal of Chinese Medicine, January 2003, Vol. 31, No. 03 : pp. 415-423
The American Journal of Chinese Medicine, Vol. 31, No. 3, 415–423
2003 World Scientific Publishing Company and Institute for Advanced Research in Asian Science and Medicine
doi: 10.1142/S0192415X0300103X
References (pg. 9 of PDF):
1988 – LIAU, M.C., … and S.R. BURZYNSKI – … antineoplaston A5
1990 – LIAU, M.C. and S.R. BURZYNSKI – … anticancer components of antineoplaston A2, A3 and A5
Cited by (pg. 10 of PDF):
2012 – 2. Zirong CHEN, … – … CDA- II …
2006 – 3. … , M.C. LIAU, … – Inhibitory effect of CDA-II, a urinary preparation, …
http://www.worldscientific.com/doi/abs/10.1142/S0192415X0300103X
PDF
http://www.worldscientific.com/doi/pdf/10.1142/S0192415X0300103X
PDF+
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X0300103X
PDF+
Burzynski References: 12 – 13
http://www.worldscientific.com/doi/ref/10.1142/S0192415X0300103X
10/1/2005 – Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway
http://www.ncbi.nlm.nih.gov/m/pubmed/16296925
… HUMAN URINE extract …
HUMAN URINE preparation, CDA-2
Everlife Biotechnology Ltd./Incubator of
Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan, ROC
J Altern Complement Med. 2005 Oct;11(5):903-8
The Journal of Alternative and Complementary Medicine
Vol. 11: 903-908 (Volume publication date: October 2005)
DOI: 10.1089/acm.2005.11.903
http://online.liebertpub.com/doi/abs/10.1089/acm.2005.11.903

http://online.liebertpub.com/doi/abs/10.1089/acm.2005.11.903

http://ir.nhri.org.tw/handle/3990099045/2796
4/1/2006 (10/17/2005) – Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes
http://www.ncbi.nlm.nih.gov/m/pubmed/16229933
The effects of CDA-II (cell differentiation agent II; a URINARY preparation) …
M.C. LIAU et al
Department of Pharmacology, China Medical University, Taiwan, ROC
Food Chem Toxicol. 2006 Apr;44(4):546-51. Epub 2005 Oct 17
http://www.sciencedirect.com/science/article/pii/S0278691505002875

http://www.sciencedirect.com/science/article/pii/S0278691505002875

6/8/2012 – Taiwan, ROC
CDA-II (cell differentiation agent II), isolated from healthy HUMAN URINE
Biochem Biophys Res Commun. 2012 Jun 8;422(3):522-6. doi: 10.1016/j.bbrc.2012.05.068. Epub 2012 May 22
http://www.ncbi.nlm.nih.gov/m/pubmed/22627135

http://www.sciencedirect.com/science/article/pii/S0006291X1200945X

Burzynski and China / Taiwan, ROC

http://www.china-burzynski.com

http://www.china-burzynski.com/lczl/bingrengushi_135135.html

http://www.china-burzynski.com/lxwm
Below is information I have located re CDA-2 research in Taiwan, ROC and China

The history of CDA-2 (CDA-H or CDA-II) in Taiwan, ROC and China:

(Please note the numerous references to Liau & Burzynski)

1999 – Liao MC – A clever anticancer drug CDA-H
Taipei: ShiMao publisher
1999; 149–161

2000 – China – Antitumor effect of CDA-2 … (6. Publications Reference 8.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21

2000 – China – HUMAN URINE extracts (CDA-II) as a novel anticancer agent … – NHRI Conf. New Drug Dev. Chin. Med (Abstract), p. 12, 2000 (listed as Reference on pg. 9 of PDF)
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X0300103X

2000 – Taiwan, ROC – HUMAN URINE extracts (CDA-II) as a novel anticancer agent …
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21

2001 – Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain
http://www.ncbi.nlm.nih.gov/m/pubmed/11321484
– …, LIAU MC, …
Department of Pharmacology, China Medical College, Taichung, Taiwan, ROC
Am J Chin Med. 2001;29(1):91-9
References:
1988 – 3. BURZYNSKI, S.R. – … antineoplastons
1992 – 29. SAMID, D., S. … – Phenylacetate: …
http://www.worldscientific.com/doi/abs/10.1142/S0192415X01000101
PDF
http://www.worldscientific.com/doi/pdf/10.1142/S0192415X01000101
PDF+
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X01000101
Cited by:
1/2009 – China – 1. CDA-II, a URINARY …
2008 – China – 2. HUMAN URINE extract CDA-2 …
10/2005 – Taiwan, ROC – 3. … HUMAN URINE Extract
6/2005 – China – 4. Anti-tumor effect of CDA-II …
2003 – China / Taiwan, ROC – 5. …, Ming-Cheng LIAU, … Effect of CDA-II …
2002 – CHEN CH, … – CDA-Ⅱ … The 7th Taiwan Joint Cancer Conference ([ Conference Abstracts] Reference 5.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2002 – … HUMAN URINE extract CDA-Ⅱ … The 7th Taiwan Joint Cancer Conference ([Conference Abstracts] Reference 6. and 7.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – … , CHEN CH, … – CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] Reference 4.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – HUMAN URINE Extract CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] References 2. and 3.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21
2003 – CHEN CH, – … CDA-Ⅱ … The 10th SCBA International Symposium ([Conference Abstracts] Reference 1.)
http://share.cjfu.com/supersite/?uid-43-action-viewspace-itemid-21

1/2003 – Effect of CDA-II on Cell Viability, Lipid Peroxidation, Glutathione Concentration and Its Related Enzyme Activities in Primary Rat Hepatocytes
The American Journal of Chinese Medicine, January 2003, Vol. 31, No. 03 : pp. 415-423
doi: 10.1142/S0192415X0300103X
CDA-II (cell differentiation agent: a preparation of HUMAN URINE)
China / Taiwan, ROC
References (pg. 9 of PDF):
1988 – LIAU, M.C., … and S.R. BURZYNSKI – … antineoplaston A5
1990 – LIAU, M.C. and S.R. BURZYNSKI – … anticancer components of antineoplaston A2, A3 and A5
Cited by (pg. 10 of PDF):
2012 – 2. Zirong CHEN, … – … CDA- II …
2006 – 3. … , M.C. LIAU, … – Inhibitory effect of CDA-II, a urinary preparation, …
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X0300103X

1/2003 – Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells
http://www.ncbi.nlm.nih.gov/m/pubmed/12508353
Department of General Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, Guangdong Province, China
public.guangzhou.gd.cn
World J Gastroenterol. 2003 Jan;9(1):65-8
http://www.wjgnet.com/1007-9327/full/v9/i1/65.htm
PDF
http://www.wjgnet.com/1007-9327/9/65.pdf
1/2003
http://www.wjgnet.com/1007-9327/full/v9/i1/65.htm
PDF
http://www.wjgnet.com/1007-9327/9/65.pdf

Critics ignore CDA-2 (CDA-H or CDA-II) Phase III Clinical Trials list Burzynski as References: 7., 23., 32, and 35.
http://file.lw23.com/f/f0/f07/f074852c-64a4-4b03-8595-47a5e6609a3f.pdf
Critics should study the history of CDA-II (CDA-2 or CDA-H):
6/2005 – Burzynski References 7. and 9.
http://www.springerlink.com/content/vq43t88675366262
2003 – Burzynski References 12. and; 13.
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X0300103X
2001 – Burzynski Reference 3.
Samid Reference 29. (who learned from Burzynski)
http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X01000101
Connection between Burzynski and China under the section titled “Evaluating Antineoplaston Therapy,” there is a paragraph about 1/2 way through the article which describes this:
http://www.commonweal.org/pubs/choices/21.html
Phase I/II/III clinical trials of CDA-2 were completed in China in 2003
In August 2004, the State Drug Administration (SDA) of China approved the use of CDA-2 as an anticancer drug in solid tumors
CDA-2 had been approved as a 1st class new anti-cancer drug by the SFDA of mainland China in 2004 through the effort of both sides of the Taiwan Strait

2005 – Phase III Clinical Trials of the Cell Differentiation Agent-2(CDA2): Therapeutic Eficacy on Breast Cancer, Non-Small Cell Lung Cancer and Primary Hepatoma
Cell Differentiation Agent-2 (CDA-2) … – a URINARY preparation, …
CDA-2 & its main component PHENYLACETYLGLUTAMINE (PG) {Antineoplaston AS2-5} …
China / Taiwan, ROC
Chinese Journal of Clinical Oncology
2005/Volume2/Number4 PGA. 706-716
(PDF – 11 pgs.)
Burzynski / Liau References
1989 – 7. Liau MC, … , BURZYNSKI SR
(PDF-pg. 9 of 11)
1986 – 23. Liau MC, BURZYNSKI SR
(PDF-pg. 10 of 11)
1990 – Antineoplaston A5 – 32. Liau MC, … , BURZYNSKI SR
1987 – 35. Liau MC, … , BURZINSKY SR
http://file.lw23.com/f/f0/f07/f074852c-64a4-4b03-8595-47a5e6609a3f.pdf

6/2005 – Anti-tumor effect of CDA-II on a human glioma cell
China
Chinese Journal of Clinical Oncology
June 2005, Volume 2, Issue 3, pp 679-684
DOI
10.1007/BF02739731
http://link.springer.com/article/10.1007%2FBF02739731
References:
1999 – 2. Taiwan, ROC – Liao MC – A clever anticancer drug CDA-II
1986 – 7. BURZYNSKI SR – Antineoplastons: …
2002 – 8. China – … CDA-H …
2003 – 9. BURZYNSKI SR, … Phase II … antineoplaston A10 & AS2-1 …
2003 – 11. … CDA-II
2003 – 12. … cell differentiation agent II …
2001 – 13. … CDA-II, URINARY preparation, …

10/2005 – Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway
http://www.ncbi.nlm.nih.gov/m/pubmed/16296925
… HUMAN URINE extract …
Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan, ROC
J Altern Complement Med. 2005 Oct;11(5):903-8
http://online.liebertpub.com/doi/abs/10.1089/acm.2005.11.903

4/2006 (10/17/2005) – Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes
http://www.ncbi.nlm.nih.gov/m/pubmed/16229933
The effects of CDA-II (cell differentiation agent II; a URINARY preparation) …
Department of Pharmacology, China Medical University, Taichung 404, Taiwan, ROC
Inhibitory effect of CDA-II, a URINARY preparation, …
… LIAU MC, …
Food Chem Toxicol. 2006 Apr;44(4):546-51. Epub 2005 Oct 17
http://www.sciencedirect.com/science/article/pii/S0278691505002875

8/1/2008 – Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner
http://www.ncbi.nlm.nih.gov/m/pubmed/18664328
HUMAN URINE extract CDA-2 …
Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Acta Pharmacol Sin. 2008 Aug;29(8):951-64. doi: 10.1111/j.1745-7254.2008.00826.x
References (pg. 13 of PDF):
1986 – 5. BURZYNSKI SR – Antineoplastons: …
2000 – 6. Egypt – Potential utility of antineoplaston A-10 levels in breast cancer
2001 – 7. …, LIAU MC – Effect of CDA-II, URINARY preparation, …
2006 – 8. …, LIAU MC, … – Inhibitory effect of CDA-II, a URINARY preparation, …
2005 – 9. … HUMAN URINE extract …
http://www.nature.com/aps/journal/v29/n8/full/aps2008115a.html
PDF
http://www.nature.com/aps/journal/v29/n8/pdf/aps2008115a.pdf

9/2008 – [In vitro study of the effects of CDA-II combined with cAMP on apoptosis induction in retinoic acid resistant acute promyelocytic leukemia cells]
http://www.ncbi.nlm.nih.gov/m/pubmed/19175987
Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
2008 Sep;29(9):603-6. Article in Chinese

1/2009 (8/9/2008) – CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner
http://www.ncbi.nlm.nih.gov/m/pubmed/18761050
CDA-II, a URINARY preparation, …
CDA-II (cell differentiation agent II) was a URINARY preparation, isolated from HEALTHY HUMAN URINE
We determined the anticancer activity of CDA-II …
Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, Hangzhou, Zhejiang, People’s Republic of China
Food Chem Toxicol. 2009 Jan;47(1):40-9. doi: 10.1016/j.fct.2008.08.001. Epub 2008 Aug 9
http://www.sciencedirect.com/science/article/pii/S0278691508004249

4/2009 (10/14/2008) – Comparative proteomics and molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model
http://www.ncbi.nlm.nih.gov/m/pubmed/18853186
… CDA-II … – (cell differentiation agent-II)
Chemistry Department of Fudan University, Shanghai, China
fudan.edu.cn
J Cancer Res Clin Oncol. 2009 Apr;135(4):591-602. doi: 10.1007/s00432-008-0493-0. Epub 2008 Oct 14
References
1987 – 18. LIAU MC, … BURZYNSKI SR – … urinary … antineoplaston therapy
2006 – 19. …, LIAU MC, … – Inhibitory effect of CDA-II, a URINARY preparation, …
http://link.springer.com/article/10.1007%2Fs00432-008-0493-0

http://www.springerlink.com/content/47t5872g67727285

6/8/2012 (5/22/2012) – DNA methyltransferase inhibitor CDA-II inhibits myogenic differentiation
http://www.ncbi.nlm.nih.gov/m/pubmed/22627135
CDA-II (cell differentiation agent II), isolated from HEALTHY HUMAN URINE
CDA-2, a URINARY Preparation
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China
Biochem Biophys Res Commun. 2012 Jun 8;422(3):522-6. doi: 10.1016/j.bbrc.2012.05.068. Epub 2012 May 22
http://www.sciencedirect.com/science/article/pii/S0006291X1200945X

http://services.elsevier.com/SDWebExport/export/figure/S0006291X1200945X/1-s2.0-S0006291X1200945X-gr1.jpg/ppt

11/2012 – CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma
Cell differentiation agent-2 (CDA-2) is an extraction from HEALTHY HUMAN URINE …
China
Journal of Neuro-Oncology
November 2012, Volume 110, Issue 2, pp 179-186
10.1007/s11060-012-0961-x
References:
2005 – 1. … HUMAN URINE extract …
2001 – 2. … (CDA-II) injection
2011 – 3. … CDA-2 …
2006 – 4. Effect of CDA-II …
2009 – 6. … CDA-2 …
2008 – 7. HUMAN URINE extract CDA-2 …
http://link.springer.com/article/10.1007%2Fs11060-012-0961-x

http://www.springerlink.com/content/w40102w0qm212g44

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117

12/17/2012 – CDA-2, a urinary preparation, inhibits lung cancer development through the suppression of NF-kappaB activation in myeloid cell.
http://www.ncbi.nlm.nih.gov/m/pubmed/23284890
CDA-2, a URINARY preparation, …
– … (cell differentiation agent 2) …
Department of Pharmacy, Putuo People’s Hospital, Shanghai, China
PLoS One. 2012;7(12):e52117. doi: 10.1371/journal.pone.0052117. Epub 2012 Dec 17
References (pg. 10 of PDF):
2009 – 3. CDA-II, a URINARY preparation, …
2006 – 4. …, LIAU MC, … – Inhibitory effect of CDA-II, a URINARY preparation, …
2005 – 5. … HUMAN URINE extract …
2008 – 6. HUMAN URINE extract CDA-2 …
2009 – 7. … CDA-2 …
(pg. 11 of PDF)
1995 – 22. …, Burzynski SR – …
antineoplaston AS21 …
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524164
PDF
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524164/pdf/pone.0052117.pdf

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0052117